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ABSTRACT
Albuminuria is an indicator of cardiovascular risk and renal damage in hypertensive 
individuals. Chronic renin–angiotensin system (RAS) suppression facilitates blood 
pressure control and prevents development of new-onset-albuminuria. A significant 
number of patients, however, develop albuminuria despite chronic RAS blockade, 
and the physiopathological mechanisms are underexplored. Urinary exosomes reflect 
pathological changes taking place in the kidney. The objective of this work was to 
examine exosomal protein alterations in hypertensive patients with albuminuria in the 
presence of chronic RAS suppression, to find novel clues underlying its development. 
Patients were followed-up for three years and were classified as: a) patients with 
persistent normoalbuminuria; b) patients developing de novo albuminuria; and c) 
patients with maintained albuminuria. Exosomal protein alterations between groups 
were identified by isobaric tag quantitation (iTRAQ). Confirmation was approached 
by target analysis (SRM). In total, 487 proteins were identified with high confidence. 
Specifically, 48 proteins showed an altered pattern in response to hypertension and/
or albuminuria. Out of them, 21 proteins interact together in three main functional 
clusters: glycosaminoglycan degradation, coagulation and complement system, 
and oxidative stress. The identified proteins constitute potential targets for drug 
development and may help to define therapeutic strategies to evade albuminuria 
progression in hypertensive patients chronically treated.
INTRODUCTION
Hypertension is a major risk factor for cardiovascular 
and renal disease. In patients with primary hypertension and 
normal renal function, increased urinary albumin excretion 
(albuminuria) is a marker of cardiovascular disease 
progression and of renal function worsening [1–3]. Its 
predictive capacity is based on the fact that microvascular 
damage is present in the kidney and this and other forms 
of target organ damage have been shown to predict 
mortality even when global cardiovascular risk (SCORE-
based evaluated) is not elevated [4]. Chronic suppression 
of the renin–angiotensin system (RAS) has been shown 
to facilitate blood pressure (BP) control and prevent the 
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development of new-onset albuminuria [5]. Nonetheless, 
we and others have shown that hypertensive patients under 
chronic RAS suppression may present albuminuria; in 
particular, de novo albuminuria developed in up to 16.1% 
of normoalbuminuric patients during a three–year period 
of follow-up [6, 7]. The physiopathological mechanisms 
mediating albuminuria progression in hypertensive 
patients under chronic RAS suppression are, however, 
underexplored. 
Exosomes are biological messengers with proven 
roles in regulating immune response, antigen presentation, 
RNA and protein transfer, and cell–cell interaction/
signaling. Exosomes from the renal system may provide 
with novel clues in the clinical setting of albuminuria 
[8, 9, 10]. Indeed, urinary exosomes contain proteins 
characteristic of every renal tubule epithelial cell type 
and from the urinary collecting system, including proteins 
that are characteristic of the membrane and cytoplasm 
of the cells in which they have been generated. As such, 
they should be regarded not only as waste disposal units, 
but also as messengers, carrying molecular indicators 
of renal dysfunction and structural injury [11]. This role 
for exosomes gains particular importance in complex 
scenarios where multi-organ crosstalk takes place 
[8, 12]. We previously showed that urinary exosomes 
reflect protein changes taking place in the kidney in 
diabetic nephropathy [13], thus constituting an accessible 
source of “information” compared to renal biopsy. 
Additionally, exosomes constitute a sub-proteome of 
the urine and its analysis allow approaching molecular 
changes that otherwise are hidden if pursued in the whole 
urine. Previous studies from our group showed molecular 
fingerprints in urine and plasma linked to albuminuria 
development in hypertensive patients who are under 
chronic RAS suppression. In this study, we investigate a 
potential role for urinary exosomes in the search for novel 
markers in this clinical setting. 
RESULTS
Exosomal proteins identified in hypertensive 
patients under chronic RAS suppression
Urinary exosomes and their potential role in 
the physiopathological mechanisms responsible for 
albuminuria development in hypertensive patients under 
chronic RAS suppression were investigated. Quantitative 
iTRAQ-LC-MS/MS proteomic analysis was used to 
explore exosomal protein alterations, allowing deep 
coverage of the analyzed proteome as previously shown 
in plasma in this clinical setting [14]. The present work 
focused on proteins. While intact endogenous peptides are 
also of great interest, and for which different analytical 
strategies should be applied, they were beyond the scope 
of the present study. Urine exosome samples from the 
23 subjects (5 control and 18 hypertensive patients) 
were used for iTRAQ analysis. Two biological replicates 
were analyzed per group with each comprising 2–4 
individual samples (see Supplementary Figure 1 for 
experimental design). Proteomic data derived from this 
study are deposited in Peptide-Atlas (accession number 
PASS00970).
A total of 487 proteins with more than 3 peptides 
were identified in urinary exosomes (Supplementary 
Table 1). Among these, 100 proteins were identified for the 
first time in urinary exosomes according to the ExoCarta 
database (Supplementary Table 2). Exosomal markers 
including Tsg101, CD63, annexins A3, A4, A5, A6, and 
A7, flotillin-1, clathrin1, and LAMP1 were identified and 
no significant differences were found between N, dnA and 
MHA groups confirming un-biased exosomal isolation. 
Some of the identified proteins have been previously 
assigned specifically to Bowman’s capsule, proximal 
tubule, loop of Henle, distal tubule, collecting duct or 
bladder, and no differences in response to albuminuria or 
hypertension were detected (Supplementary Table 3). 
Exosomes have distinct protein signatures in 
response to albuminuria
Proteins whose levels were identified to be altered 
were those with a significance cut off value of Zq ≥ 1.4 
(absolute value) versus the control group, and showing 
intra-group consistency of variation between the two 
biological replicates analyzed per group. With these 
criteria, iTRAQ quantitative analysis revealed 48 proteins 
(out of the 487 identified) showing altered levels in 
hypertensive patients under chronic RAS suppression as 
compared with healthy subjects (Table 1). The magnitude 
of protein alteration in Table 1 is represented by a heat 
map (red, up-regulation; green, down-regulation versus 
the control group). Three main trends could be observed, 
being up- or down-regulated in response to: hypertension 
without albuminuria (9 proteins), maintained albuminuria 
(18 proteins), and de novo albuminuria (21 proteins). 
According to the Human Protein Atlas, 56% of the 
identified proteins have annotated expression in the 
kidney, mainly in the tubule (26 proteins) but also in the 
glomerulus (13 proteins). The majority of these proteins 
were also identified in a recent study characterizing the 
proteome of urinary exosomes specifically released by 
podocytes [15].
We evaluated a sub-set of representative proteins 
significantly responding to de novo albuminuria, 
myeloperoxidase (MPO), olfactomedin-4 (OLFM4) 
and antithrombin-III (AT3), using a different analytical 
technique (SRM-LC-MS/MS) in an independent cohort 
of 40 non-diabetic hypertensive patients under chronic 
suppression of RAS and in 14 healthy subjects. In this 
target analysis, all subjects who were recruited for the 
iTRAQ analysis (but two control individuals) were 
included, and individual samples (not pools) were 
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Table 1: Proteins identified in urinary exosomes from hypertensive patients under chronic RAS 
suppression showing significantly altered levels in response to albuminuria







Proteins responding to maintained albuminuria
P01859 IGHG2 Ig gamma-2 chain C region 11 -
P02750 LRG1 Leucine-rich alpha-2-glycoprotein 11 T
P04217 A1BG Alpha-1B-glycoprotein 11 -
P25311 AZGP1 Zinc-alpha-2-glycoprotein 10 T
P15586 GNS N-acetylglucosamine-6-sulfatase 6 G,T
P04066 FUCA1 Tissue alpha-L-fucosidase 5 T
P34059 GALNS N-acetylgalactosamine-6-sulfatase 5 G,T
Q9BTY2 FUCA2 Plasma alpha-L-fucosidase 4 T
P07355 ANXA2 Annexin A2 36 G,T
P04083 ANXA1 Annexin A1 29 G
P10253 GAA Lysosomal alpha-glucosidase 30 T
P01011 SERPINA3 Alpha-1-antichymotrypsin 14 -
P08236 GUSB Beta-glucuronidase 14 G,T
P15289 ARSA Arylsulfatase A 11 G,T
P00747 PLG Plasminogen 8 T, I [57]
P51688 SGSH N-sulphoglucosamine sulphohydrolase 5 T
B9A064 IGLL5 Immunoglobulin lambda-like polypeptide 5 5 T
P05543 SERPINA7 Thyroxine-binding globulin 11 -
Proteins responding to de novo albuminuria (earlier response)
P00450 CP Ceruloplasmin 35  PECs [58]
P01024 C3 Complement C3 57  PT, I [59]
P01009 SERPINA1 Alpha-1-antitrypsin 32 T
P02787 TF Serotransferrin 31 PTECs [60]
P49221 TGM4 Protein-glutamine gamma-glutamyltransferase 4 16 -
P0C0L4 C4A Complement C4-A 41 T [59]
P16278 GLB1 Beta-galactosidase 14 G,T
P01857 IGHG1 Ig gamma-1 chain C region 14 -
A2BHY4 C4B-1 Complement component C4B 5 T [59]
P01620 Ig kappa chain V-III region SIE 4 -
Q96P63 SERPINB12 Serpin B12 7 T
P07339 CTSD Cathepsin D 13 G,T
Q6UX06 OLFM4 Olfactomedin-4 21 T [61]
P01008 SERPINC1 Antithrombin-III 8 G,T
P02511 CRYAB Alpha-crystallin B chain 7 G,T
P05164 MPO Myeloperoxidase 11 inflitrates [62]
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analyzed. A specific SRM assay was developed with high 
sensitivity and high-throughput capacity in alignment with 
our previously published study in urine [16]. Changes 
in their levels were confirmed for three representative 
proteins, OLFM4, AT3 and MPO, chosen in view that they 
showed variation in dnA, which is an earlier response in the 
pathological process, their variation rate, their abundance 
(estimated in view of number of identified peptides) or their 
relationship with other proteins previously identified in 
plasma/urine in this clinical context (e.g. ceruloplasmin or 
MMP9). OLFM4 and AT3 levels were increased and MPO 
was decreased in the dnA group. Receiver operating curves 
showed good sensitivity and specificity in differentiating 
the dnA group from the control group, with t-test values 
of 0.029 (MPO), 0.0089 (AT3) and 0.0097 (OLFM4) and 
area under the curve (AUC) values were 0.767, 0.862 and 
0.917, respectively (Figure 1).
Biological response and protein interaction 
networks
Significantly enriched GO terms (p-value < 0.05) 
of the main biological processes identified from protein 
alterations in response to hypertension and albuminuria 
progression revealed the involvement of inflammatory 
response, defense and wounding (Figure 2). In particular, 
the altered proteins are major players in immune 
response, complement activation, proteolysis and 
metabolic processes, mainly related to metabolism of 
sulphur compounds, lipids and polysaccharides. Protein-
protein interaction networks revealed that 21 out of those 
48 proteins interacted together, and are implicated in three 
main functional clusters: “glycosaminoglycan (GAG) 
degradation”, “coagulation and complement system”, and 
“oxidative stress” (graphically summarized in Figure 3).
DISCUSSION
Hypertension is associated with end-organ damage, 
particularly affecting heart, vessels and kidney, leading 
to significant worsening of cardiovascular and renal 
prognosis. Albuminuria is an indicator of cardiovascular 
risk and of end-stage renal disease. We recently reported 
significant alterations in proteins from urine and plasma 
in response to albuminuria and its de novo development 
in these hypertensive patients [14, 16, 17], demonstrating 
that subjacent biological mechanisms have a measurable 
molecular phenotype in biological fluids which, in some 
cases, may allow for anticipating the response of the 
traditional clinical marker (albuminuria). Exosomes have 
P08571 CD14 Monocyte differentiation antigen CD14 16 -
P00915 CA1 Carbonic anhydrase 1 9 -
O00187 MASP2 Mannan-binding lectin serine protease 2 9 G,T
P02730 SLC4A1 Band 3 anion transport protein 8 T
P05090 APOD Apolipoprotein D 7 -
Proteins responding to hypertension with normoalbuminuria
P05154 SERPINA5 Plasma serine protease inhibitor 21 T
P05109 S100A8 Protein S100-A8 18 inflitrates [63]
P06702 S100A9 Protein S100-A9 15 inflitrates [63]
Q6UVK1 CSPG4 Chondroitin sulfate proteoglycan 4 4 G,T
P12277 CKB Creatine kinase B-type 12 -
P01133 EGF Pro-epidermal growth factor 26 T
P01023 A2M Alpha-2-macroglobulin 18 G,T
Q6UX73 C16orf89 UPF0764 protein C16orf89 4 T
Q14624 ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 14 T
Colour-grade scale refers to the magnitude of the alteration versus the control group: red, up-regulation; green, down-
regulation. 
Differentially expressed proteins were those identified with more than three peptides and Zq ≥ 1.4 (absolute value) versus 
control group (p-value ≤ 0.05). Zq denotes the mean for the two biological replicates analyzed per group. 1Identified peptides 
by LC-MS/MS. G: glomerulus; T: tubule; -: no data; PTECs (proximal tubular epithelial cells); I (interstitium); PECs 
(parietal epitheilal cells); PT (proximal tubule). Annotated expression in kidney: Human Protein Atlas (HPA).
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been shown to reflect molecular changes taking place in 
kidney tissue from patients with diabetic nephropathy 
[13]. In the present study we searched for the strongest 
variations in urinary exosomes linked to albuminuria, in 
search of a better understanding of the interconnected 
dynamic processes taking place in the non-diabetic 
hypertensive kidney under chronic RAS suppression.
Glomerular basement membrane disruption, 
proteases inhibition and inflammatory response
Enzymes linked to the GAG pathway, specifically 
beta-galactosidase (GLB1), beta-glucuronidase (GUSB), 
N-acetyl-glucosamine-6-sulfatase (GNS) and N-acetyl-
galactosamine-6-sulfatase (GALNS), were increased in 
the MHA group, and GLB1 was also increased in the dnA 
group (Figure 4). These four enzymes are responsible for 
the GAG degradation and may be related to glomerular 
basement membrane (GBM) disruption, which could 
lead to defective filtering [18]. One of the degradation 
products that would be enhanced in pathologic conditions 
is the proteoglycan heparan sulphate. Previous findings 
suggest that heparan sulphate facilitates the passage 
of proteins through the GBM [19]. This proteoglycan 
binds to and modulates the effects of several proteins, 
including heparin-dependent serine protease inhibitors 
such as antithrombin III (AT3, SerpinC1) and protein 
C inhibitor (PCI, PAI-3, SerpinA5) [20], both of which 
we found increased in urinary exosomes of hypertensive 
patients. AT3 is related to homeostasis in the kidney, 
and its concentration in urine correlates with albumin 
and plasminogen (PLG) excretion [21]. The main 
source of PCI is liver; however, its synthesis has also 
been reported in kidney where it is produced mainly by 
proximal tubular epithelial cells (PTECs) [22]. PCI is a 
pro-coagulant and pro-inflammatory protein that inhibits 
urinary plasminogen activator (uPA), a serine protease that 
activates plasminogen by converting it to plasmin, which 
acts to lyse fibrin clots. PLG is synthesized in liver but 
often extravasates during inflammation. We also found 
increased PLG in urinary exosomes from the MHA group. 
PLG can bind to annexin A2 (ANXA2), promoting its 
activation to form plasmin [23].We found decreased levels 
of exosomal ANXA2 and ANXA1 in the MHA group. 
Annexins are a family of calcium-dependent phospholipid-
binding proteins with anti-inflammatory activity [24]. 
Down-regulation of both ANXA1 and ANXA2 exosomal 
proteins is in agreement with a pro-inflammatory scenario 
in this clinical context.
Two exosomal proteins whose levels were altered 
in the normoalbuminuric (N) group as compared with 
controls are also involved in coagulation and inflammatory 
Figure 1: Confirmation of proteins variation by target analysis. SRM-LC-MS/MS analysis confirmed previous variations 
identified by iTRAQ for three representative proteins showing significant alteration in response to dnA (early response): MPO (A), OLFM4 
(B) and AT3 (C). Non-parametric Kruskal-Wallis test with Dunn’s multiple comparisons post-test and 95% confidence level was performed 
between each pathological condition (N, dnA, MHA) and control (C). (Panels D to F) show receiver operating curves (ROC) for these 
proteins, respectively; t-test values were 0.029 (MPO), 0.0089 (AT3) and 0.0097 (OLFM4).
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response: epithelial growth factor (EGF), which was 
increased, and a-2 macroblobulin (A2M), which was 
decreased. EGF in the kidney is a modulator of glomerular 
dynamics, renal metabolism and tubular transport, and 
plays a role in maintaining and repairing the epithelium 
[25]. A2M is a major inhibitor of proteases in body 
fluids and is the most important inhibitor of circulating 
metalloproteinases (MMPs) [26]. The response of the two 
proteins, displaying alterations at an early stage when 
albuminuria is not present, point to subjacent de-regulation 
of renal metabolism. The decrease in the level of A2M 
in the N group, together with the up-regulation observed 
for the GAG degradation pathway in albuminuria are in 
agreement with a deleterious remodeling of the GBM 
involving pathological MMP-9 activity, which might 
contribute to glomerular hyperfiltration, albuminuria 
escape and loss of renal function, as previously published 
by us [27]. 
The level of alpha-1 antitrypsin (AAT, SerpinA1), 
a heparin-independent serine protease inhibitor, was 
significantly increased in exosomes from albuminuric 
patients, which is consistent with our previous finding that 
AAT levels are increased in whole urine from hypertensive 
patients who develop albuminuria [16]. AAT has also been 
suggested to regulate inflammation and the accumulation of 
mesangial matrix, protecting the urinary tract against attack 
by proteases, and could be a marker of podocyte stress [28].
Complement system and inflammatory response
A sub-set of the identified proteins is linked to the 
complement system, as part of the immune response [29]. 
The complement system has three activation pathways: 
the classical, alternative, and lectin pathways. The level 
of mannose-binding lectin (MBL)-associated serine 
protease-2 (MASP-2) was decreased in exosomes from 
the dnA group, while components C3, C4a and C4b 
were increased in albuminuria condition, pointing to a 
disfavored lectin pathway. Levels of complement C3 
and C4 are also increased in chronic inflammation [30]. 
Moreover, excess protein traffic occurs in proteinuric 
nephropathies, causing an inflammatory response with 
local increases in C3 [31], and high baseline levels of C3 
correlate with higher risk of developing hypertension, 
diabetes mellitus or myocardial infarction [30]. Our data 
are in accord with these previous observations. 
Oxidative stress
We detected an increase in the levels of transferrin 
(TF) in exosomal fractions of hypertensive patients 
with albuminuria. Transferrin is an iron-binding serum 
protein that upregultaes C3 synthesis in PTECs [32]. 
The iron moiety of transferrin is toxic to PTECs as a 
result of intracellular iron accumulation and peroxidative 
Figure 2: Significantly enriched processes (p-value < 0.05) identified for the entire set of 48 altered proteins in response 
to hypertension and albuminuria. The percentage of genes associated with each biological process is represented.
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injury after reabsorption. Conversely, iron depletion was 
shown to have a positive effect in inhibiting oxidative 
stress in experimental diabetes [33]. Our data indicate 
an accumulation of transferrin in kidney in albuminuria, 
with a potential deleterious effect via excess iron 
accumulation. Ceruloplasmin (CP) levels were also found 
increased in patients with hypertension and albuminuria. 
CP is a copper-containing glycoprotein antioxidant that 
may function as a pro-oxidant in conditions of increased 
oxidative stress by inducing ROS production and low-
density lipoprotein oxidation [34]. We detected a positive 
correlation between CP levels in urinary exosomes and 
increased albuminuria, as we previously described for 
plasma CP from hypertensive patients under chronic RAS 
suppression who progress to albuminuria [17].
CP also acts by binding to and inhibiting the activity 
of myeloperoxidase (MPO) [35], the exosomal levels of 
which were decreased in the dnA group. Following the 
same trend than observed for MPO in the N and dnA 
groups were two intracellular calcium-binding proteins, 
S100A8 and S100A9, which form the heterodimer 
calprotectin. MPO and calprotectin have been shown to 
work synergistically to stimulate ROS formation [36]. 
Additionally, calprotectin also inhibits MMPs, whose 
activities were previously found to be increased in this 
clinical setting [27]. While an increase in the level of blood 
S100 proteins in response to inflammation has been widely 
documented and positively correlate with cardiovascular 
risk, diabetes and proteinuria [37, 38], the opposite 
was found here for exosomal fractions in hypertensive 
patients with incipient or no albuminuria, which showed 
decreased levels of S100A8 and S100A9. This may be 
explained on the basis of tissue repair mechanisms. In 
kidney disease, controversy exists over the beneficial/
deleterious effect of M1/M2 macrophage polarization. In 
one study, a shift in macrophage polarization from M1 to 
M2 was related to a decrease in albuminuria [39], while 
in another study, repolarization to M1 by drug treatment 
inhibited kidney damage progression [40]. In an ischemia-
reperfusion-induced injury model, mice genetically 
deficient for calprotectin presented an increase in 
M2-polarized macrophages during the repair phase, 
Figure 3: Functional analysis of protein variations. String pathway analysis revealed three main clusters of interaction, pointing 
to glycosaminoglycan (GAG) degradation, coagulation and complement system, and oxidative stress as main physiopathological processes 
underlying hypertension under chronic RAS suppression and albuminuria development. 
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leading to ineffective tissue repair, increased renal damage 
and sustained inflammation [41]. This tissue repair effect 
may require physical contact between the M2 macrophage 
and the injured tubular epithelial cell [42], which we 
hypothesize could be mediated by exosomes. Our data 
are in agreement with an inefficient tissue repair at early 
stages in albuminuria development and maintenance.
This is an initial study that focuses on a largely 
unexplored clinical field. We have identified protein 
changes in urinary exosomes from hypertensives 
developing albuminuria, despite of chronic RAS 
suppression with different variation trends. In particular, 
some proteins show a dynamic change in the sense that 
they respond to dnA and apparently return to normalized 
levels in MHA. This finding, also observed in specific 
metabolites as shown in previous studies, is not surprising 
and we can hypothesized that the mechanisms operating 
when the conditions for a progression of albuminuria are 
present are reset once albuminuria is more established. 
The main limitation of the present study is the low number 
of patients and thus the clinical usefulness of the exosomal 
proteins identified and the proposed physiological 
changes taking place linked to albuminuria development 
in hypertensive patients under chronic suppression of 
RAS should be validated in larger multicenter cohorts. 
Although unavoidable, a potential bias regarding patients’ 
medication compared to control individuals could be a 
limitation of the study. However, particular attention was 
paid to protein changes with albuminuria development and 
no significant differences were observed between patients’ 
groups. All them were under RAS suppression and other 
drugs, if necessary. As a strength, we would highlight 
that this is the first study to explore exosomes as a novel 
source of diagnostic/prognostic markers for albuminuria 
development in this context. The present findings 
complement and extend our previous work in urine, 
plasma and circulating extracellular vesicles. We believe 
that exosomes contain clues to understand the diverse 
progression of hypertension under chronic treatment, and 




A schematic workflow is shown in Figure 5. Patient 
selection was based on a previous study showing the 
development of de novo albuminuria in hypertensive 
patients during chronic RAS suppression [7]. In that 
study, the evolution of patients from the Hypertension 
Unit-Hospital 12 de Octubre who had been under chronic 
Figure 4: Overview of main altered protein patterns identified in exosomes from hypertensive patients under chronic 
RAS suppression developing albuminuria. Trends refer to control group. Analysis of urinary microvesicles allows a closer view of 
the changes potentially taking place in the kidney that otherwise could not be accessed non-invasively. 
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RAS suppression for at least five years was reviewed. 
Baseline data were obtained after a 3-month stabilization 
period. From baseline, patients were subsequently 
followed for a minimum period of three years, during 
which time progression to albuminuria was evaluated. 
RAS suppression was maintained during the entire 
length of follow-up. Of the normoalbuminuric patients 
at baseline, 16.1% developed de novo albuminuria 
(i.e., absent at baseline and developed later) during the 
3-year period. De novo albuminuria development was 
defined as either new-onset high albuminuria (albumin-
to-creatinine ratio 20–200 mg/g of creatinine in men and 
30–300 mg/g of creatinine in women) confirmed in at least 
a second occasion among the 6-monthly determinations 
performed in three samples of early-morning urine, or 
very high albuminuria (> 200 mg/g creatinine in men 
and > 300 mg/g creatinine in women). We performed 
exosomal analysis at the end of the third year of follow-
up. A group of 40 non-diabetic hypertensive patients were 
selected as a representative cohort and classified into the 
following three sub-groups: a) patients who remained 
normoalbuminuric during the follow-up (defined as N); 
b) patients developing de novo albuminuria during the 
follow-up (defined as dnA); and c) patients with persistent 
albuminuria since baseline and during the follow-up 
(defined as MHA, maintained high albuminuria). Table 2 
lists the baseline characteristics and medication of patients. 
The presence of secondary forms of arterial hypertension 
and diabetes mellitus were excluded. A control group of 
16 healthy normotensive subjects (defined as C) was also 
included (Table 3). The study fulfilled the requirements 
of an “Omics” study in terms of group size and technical 
workflow [43]. The clinical study was approved by the 
Ethics Committee of the Hospital 12 de Octubre and was 
conducted according to the principles of the Declaration 
of Helsinki. All patients signed written informed consent 
before inclusion. 
Urine collection and exosome isolation
Urine collection and exosome isolation based on 
ultracentrifugation were performed as described [13]. 
Briefly, morning urine was collected in a sterile container 
and stored at −80ºC until analysis. For exosome isolation, 
urine was defrosted at 37ºC and vigorously vortexed 
centrifuged at low-speed (17000 g, 10 min, 4ºC), the 
supernatant was collected and the pellet was treated with 
200 mg/mL dithiothreitol (DTT) in isolation solution 
(10 mM triethanolamine, 250mM sucrose, pH 7.6), heated 
at 37ºC for 10 min to reduce Tamm-Horsfall polymeric 
protein, releasing entrapped exosomes and increasing 
exosomal recovery [13, 44, 45]. After a new low-speed 
Figure 5: Schematic representation of the study workflow. Urine samples from 40 non-diabetic hypertensive patients and 16 
healthy controls were collected. In iTRAQ experiment 5 control samples and 18 patients, 6 of each group, were included (6 N, 6 dnA 
and 6 MHA). By SRM, samples from the 40 hypertensives and from 14 healthy controls were analyzed individually. C: control, N: 
normoalbuminuria, dnA: de novo albuminuria, MHA: maintained albuminuria, UC: ultracentrifugation, SRM: selected reaction monitoring, 
MCX: mixed-cation exchange, HTN: hypertension.
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centrifugation (17000 g, 10 min) the resulting pellet was 
discarded and the supernatant was pooled together with 
the supernatant from the first centrifugation step. This was 
then centrifuged at 175000 g for 70 min at 4ºC to pellet 
the exosomes. Isolated exosomes were characterized by 
electronic microscopy. The typical shape of exosomes 
(double membrane, cup-shaped vesicles) and appropriate 
size in the range of 50–100 nm was observed [45].
Identification of exosomal target proteins in 
hypertensive patients under chronic RAS 
suppression: iTRAQ-LC-MS/MS differential 
analysis 
From the 40 non-diabetic hypertensive patients and 
16 healthy controls referred above, urine samples from 5 
control subjects and 18 hypertensive patients were used for 
exosome extraction and quantitative differential analysis 
by liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS). Patients were classified into N 
(n = 6), dnA (n = 6) and MHA (n = 6) groups. Isobaric tags 
for relative and absolute quantification (iTRAQ, 8-plex) 
labelling was performed as described [14]. Two biological 
replicates (pools) were analyzed per group (C, N, dnA 
and MHA), with each comprising 2–4 individual samples 
(Supplementary Figure 1). One hundred micrograms of 
total protein from each biological replicate was loaded 
onto an SDS-PAGE gel to concentrate all the proteins in 
a single band. Gel bands were reduced with 10 mM DTT, 
alkylated in 50 mM iodoacetamide, and digested overnight 
at 37ºC with 80 ng/mL of modified trypsin (Promega, 
Madison, WI, USA). The resulting tryptic peptides 
were extracted by incubation in 12 mM ammonium 
bicarbonate pH 8.8 and later, 0.5% trifluoroacetic acid 
Table 2: Baseline characteristics and medication of patients 
Baseline characteristics  N (n = 19) dnA (n = 11) MHA (n = 10) p-value
  Age (years) 61 ± 9 65 ± 9 63 ± 9 0.362
  Total cholesterol (mg/dl) 197 ± 34 170 ± 13 187 ± 21 0.032
  Triglycerides (mg/dl) 121 ± 50 106 ± 50 120 ± 39 0.34
  HDL cholesterol (mg/dl) 53 ± 12 50 ± 17 49 ± 9 0.493
  LDL cholesterol (mg/dl) 120 ± 33 97 ± 14 115 ± 21 0.056
  Glycemia (mg/dl) 105 ± 12 99 ± 9 100 ± 12 0.321
  Uric acid (mg/dl) 5.1 ± 1.8 6.1 ± 1.6 5.7 ± 1.5 0.373
  eGFR (ml/min/1.73m2) 88 ± 11 81 ± 17 79 ± 20 0.464
  Systolic blood pressure (mmHg) 137 ± 15 131 ± 20 137 ± 19 0.616
  Diastolic blood pressure (mmHg) 83 ± 9 77 ± 10 84 ± 12 0.273
  ACR (mg/g) 8 ± 7 83 ± 38 125 ± 125 < 0.0001
Medications
 Antihypertensives, %     
     ACEi 11 9 30 0.316
     ARB 67 64 70 0.849
     Diuretic 43 36 50 0.793
     Calcium channel blocker 33 18 60 0.148
     Beta blocker 19 18 60 0.061
 Other treatments, %     
    Anticoagulant agent 24 27 20 0.916
    Lipid lowering agents 68 55 80 0.467
    Antidiabetic agent 0 0 0 > 0.9999
    Antialdosteronics 21 18 10 0.761
    Hypouricemics 0 18 0 0.067
Values expressed as mean ± SD or percentages (%). BMI: body mass index; HDL: high-density lipoprotein cholesterol; LDL: 
low-density lipoprotein cholesterol; N: normoalbuminuria; dnA: de novo albuminuria; MHA: maintained high albuminuria; 
ACR: albumin creatinine ratio; eGFR: estimated glomerular filtration rate.
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(TFA). TFA was added to a final concentration of 1% 
and the peptides were desalted onto C18 Oasis-HLB 
cartridges and dried-down for further analysis. For stable 
isobaric labeling, the tryptic peptides were dissolved in 
triethylammonium bicarbonate (TEAB) buffer, and the 
peptide concentration was determined by measuring amide 
bonds with the Direct Detect system (Millipore, Billerica, 
MA, USA). Equal amounts of each peptide sample were 
labeled using the 8-plex iTRAQ Reagents Multiplex Kit 
(Applied Biosystems, Foster City, CA, USA) according to 
manufacturer›s protocol. Samples were then concentrated 
in a Speed Vac, desalted onto C18 Oasis-HLB cartridges 
and dried-down for further analysis. To increase proteome 
coverage, iTRAQ-labeled samples were fractionated by 
mixed-cation exchange chromatography (Oasis HLB-
MCX columns) into six fractions, and analyzed by 
LC-MS/MS on an Orbitrap Elite mass spectrometer 
(Thermo Fisher Scientific, Waltham, MA, USA) using 
a C-18 reversed phase nano-column (75 µm internal 
diameter × 50 cm, 2 µm particle size, Acclaim PepMap 
RSLC, 100 C18; Thermo Fisher Scientific) in a 
continuous acetonitrile gradient consisting of 0–30% B 
in 360 min, 50–90% B in 3 min (A = 0.1% formic acid; 
B = 90% acetonitrile, 0.1% formic acid). A flow rate of 
200 nL/min was used to elute peptides from the nano-
column to an emitter nanospray needle for real time 
ionization and peptide fragmentation. An enhanced 
FT-resolution spectrum (resolution = 70,000) followed by 
the MS/MS spectra from the 15 most intense parent ions 
were analyzed along the chromatographic run. Dynamic 
exclusion was set at 40 s. For peptide identification, all 
spectra were analyzed with Proteome Discoverer (1.4.0.29, 
Thermo Fisher Scientific) using SEQUEST-HT (Thermo 
Fisher Scientific). For database searching at the Uniprot 
database, containing all sequences from human and 
cRAP contaminants (March 06, 2013; 70024 entries), the 
parameters selected were as follows: trypsin digestion with 
2 maximum missed cleavage sites, precursor and fragment 
mass tolerances of 2 Da and 0.02 Da, respectively, 
carbamidomethyl cysteine, iTRAQ modifications at 
N-terminal and Lys residues as fixed modifications, and 
methionine oxidation as dynamic modification. Peptide 
identification was validated using the probability ratio 
method [46]; false discovery rate (FDR) was calculated 
using inverted databases and the refined method [47], 
with an additional filtering for precursor mass tolerance 
of 15 ppm [48]. Protein quantification from reporter ion 
intensities and statistical analysis of quantitative data to 
identify significant proteins were performed using QuiXoT 
based on a statistical model [49]. We applied stringent 
criteria, considering differentially expressed those proteins 
identified with more than three peptides, and log2-ratios 
expressed in the form of the standardized variables (Zq) ≥ 
1.4 (absolute value) with p-values ≤ 0.05, with Zq denoting 
the mean of the two replicates versus the control group. 
Systems biology analysis
Identified proteins were compared to the entries in 
the ExoCarta database, a repository comprising proteins 
previously identified in exosomes [50]. Expression and 
localization of proteins in renal tubule and glomeruli 
were assigned by means of Human Protein Atlas [51] 
and scientific literature. PANTHER (Protein ANalysis 
THrough Evolutionary Relationships) database [52] 
and DAVID (6.7) [53] were used for protein functional 
classification. Protein pathway analysis was carried out 
using STRING 9.0 software (highest confidence, MCL 
clustering tool) [54], a database of known and predicted 
protein interactions.
Table 3: Baseline characteristics of the control group
Baseline characteristics of healthy subjects
  Age (years) 56 ± 7
  Total cholesterol (mg/dl) 199 ± 38
  Triglycerides (mg/dl) 83 ± 33
  HDL cholesterol (mg/dl) 62 ± 19
  LDL cholesterol (mg/dl) 119 ± 31
  Glycemia (mg/dl) 91 ± 13
  Uric acid (mg/dl) 4.4 ± 1.3
  eGFR (ml/min/1.73m2) 93 ± 14
  ACR (mg/g) 4 ± 3
  Systolic blood pressure (mmHg) < 140
  Diastolic blood pressure (mmHg) < 90
HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; ACR: albumin creatinine ratio; eGFR: 
estimated glomerular filtration rate.
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Target protein analysis (selected reaction 
monitoring (SRM)-LC-MS/MS)
Urine samples from the 40 non-diabetic hypertensive 
patients under chronic RAS suppression and 14 healthy 
subjects (including those analyzed by iTRAQ) were 
used for SRM-LC-MS/MS analysis. All individuals 
have been included in the iTRAQ analysis, but samples 
were analyzed by SRM individually, not including 
pools. Theoretical SRM transitions were designed using 
Skyline (1.1.0.2905) [55] and manually inspected. 
Protein specificity was confirmed by protein BLAST 
and proteotypic peptides were selected for SRM analysis 
(Supplementary Table 4). Protein extracts were obtained 
from exosomes isolated from individual urine samples. In 
total, 30 μg of protein per individual sample was digested 
and peptide mixtures were analyzed by SRM-LC-MS/MS 
as described [16, 45, 56] using a 6460 Triple Quadrupole 
LC/MS/MS (Agilent Technologies Inc., Santa Clara, CA, 
USA). Briefly, peptide separation was performed on a 
ProtID Zorbax 300B-C18-5 μm chip with a 43 × 0.075-mm 
analytical column and a 40 nL enrichment column (Agilent 
Technologies). Two microliters of sample was injected at 
3 μL/min and separation took place at 0.4 μL/min in a 
continuous acetonitrile gradient: 70% B at 10 min, 95% 
B at 12 min until 14.2 min and 0% B for 2 min (B = 0.1% 
formic acid in acetonitrile). The system was controlled by 
Mass Hunter LC–MS Acquisition Software (v4.01). The 
mass spectrometer was operated in positive ion mode with 
capillary voltage of 1970 V, 325°C source gas temperature, 
and 5 L/min source gas flow. The fragmentor was set to 
130 V, dwell time to 20 ms, delta EMV to 600 V, and 
collision energy was optimized for each SRM transition. 
For calculation of statistically significant differences 
in protein levels between groups, the ROUT method 
was applied to detect outliers based on the FDR, setting 
Q value to 5%. The Kruskal-Wallis test with Dunn’s 
multiple comparisons post-test and 95% confidence level 
was then performed. Analyses were performed using 
GraphPad Prism 6 (6.01) software (GraphPad Prism Inc., 
La Jolla, CA, USA) and Metaboanalyst web server (3.0). 
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